The Give Kids a Chance Act: Accelerating Access to Life-Saving Therapies in Pediatric Cancer
Written by: Diya Sriramagiri
For children diagnosed with cancer, access to effective treatment is often limited not by scientific possibility, but by the pace of drug development and approval. Each year, nearly 15,000 children in the United States are diagnosed with cancer, and despite advances in treatment, cancer remains the leading cause of disease-related death among children. While survival rates have improved to over 80% for some pediatric cancers, outcomes for high-risk or relapsed cancers remain significantly lower, highlighting the urgent need for more effective and timely treatment options. The Give Kids a Chance Act, reintroduced in 2025–2026, seeks to address this gap by expanding upon existing rare disease legislation to accelerate the development and availability of new therapies for children with cancer.
Pediatric cancers are often rare and biologically distinct from adult cancers, making traditional drug development pathways less effective. Although children account for a small percentage of total cancer diagnoses, only about 4–6% of federal cancer research funding is dedicated to pediatric cancers. As a result, many therapies are initially developed for adults and only later adapted for pediatric use, if they are adapted at all. This creates a critical delay in access, leaving children with limited treatment options, especially in cases of aggressive or relapsed disease where time is a determining factor in survival.
The Give Kids a Chance Act aims to shift this dynamic by requiring pharmaceutical companies to evaluate new cancer drugs for pediatric use earlier in the development process. By expanding requirements for pediatric studies and allowing combination therapies to be studied in children sooner, the legislation works to reduce the gap between scientific discovery and clinical access. This approach acknowledges that children should not have to wait years for adult-focused trials to be completed before benefiting from new therapeutic advancements. The importance of this shift lies in its ability to bridge the gap between innovation and patient access. In many cases, promising targeted therapies already exist, but structural and regulatory barriers delay their availability to pediatric patients. On average, it can take several years for drugs approved for adults to be tested and approved for children, a delay that can be life-threatening for patients with rapidly progressing cancers. Accelerating pediatric trials can provide earlier access to potentially life-saving treatments, expand options for rare and high-risk cancers, and improve both survival rates and quality of life outcomes.
However, while the Give Kids a Chance Act represents meaningful progress, it does not fully resolve disparities in access. Even when therapies are developed, systemic barriers can limit who benefits from these advancements. Studies have shown that children from underserved communities are less likely to be enrolled in clinical trials, which are often located at major academic centers. Differences in access to specialized pediatric oncology facilities, challenges in navigating insurance systems such as Medi-Cal, and broader structural inequities continue to shape outcomes. For families facing language barriers, transportation challenges, or limited healthcare access, the gap between innovation and treatment remains significant. The Give Kids a Chance Act highlights the role of policy in closing gaps between innovation and access, but it also underscores the limitations of focusing solely on research. Achieving equitable outcomes in pediatric cancer requires a more comprehensive approach that integrates scientific progress with healthcare access, community outreach, and policy reform.
As this legislation moves forward, its success will depend not only on how effectively it accelerates drug development, but on whether these advancements reach all children. For pediatric cancer patients, time is critical, and policies that reduce delays in treatment access have the potential to directly impact survival. The Give Kids a Chance Act represents an important step toward modernizing pediatric cancer care by prioritizing earlier access to innovative therapies. To fully realize its impact, however, it must be part of a broader effort to ensure that progress in science translates into meaningful and equitable outcomes for every child.
